Method for suppression of tumours growth |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
IPC classes for russian patent Method for suppression of tumours growth (RU 2339414):
 Method for electric energy production and device for its realisation / 2339152
Method for electric energy production using contacts system of nanostructured conducting surfaces with thin water layer and device for its realisation - hydroelectric generator on the base of nanostructured materials as source of electric energy are intended for obtaining electric energy using renewable energy sources. The invention is based on the fact that contacts system of nanostructured conducting surfaces with thin water layer of several nanometers to fractions of millimeter in thickness under certain conditions becomes the source of electromotive force (EMF). The invention provides electric energy production and can find wide application in various fields of science and engineering.
Mixture for production of cellular concrete / 2338712
Mixture for production of cellular concrete, which contains cement or cement and filler, water and dry cellulating mixture. Dry cellulating mixture contains the following components, wt %: carbonic nanostructures - 0.7; caustic soda - 3.3; plastifier - 6.6; gasifier - 24; quicklime and/or slaked lime, and/or chlorinated lime, and/or chalk - 65.4. Dry cellulating mixture makes 0.35-1.5% from cement mass.
Hydroreactive mixture / 2338684
Hydroreactive mixture contains industrial aluminium ACD-1 powder and aluminium nanopowder with particle size of 70÷120 nm, as well as an activating additive in form of granular sodium hydroxide with the following ratio of components, in wt %: industrial ACD-1 powder 67÷79, aluminium nanopowder 30÷14, sodium hydroxide 3÷7.
 Vertical structure of semiconductor device and method of formation thereof / 2338683
Vertical structure of semiconductor device includes substrate forming essentially horizontal plane, gate electrode with vertical side wall and vertically protruding from substrate, washer attached from one side from vertical side wall, semiconductor nanotube between gate electrode and washer and essentially vertically protruding between its opposite first and second ends, gate dielectric on vertical side wall between nanotube and gate electrode, source electrically connected with first end of nanotube, and drain electrically connected with second end of nanotube. Each nanotube is grown by chemical vapour deposition accelerated with catalyst platform mounted in foundation of elongated passage formed between washer and gate electrode.
 Sorbent for heavy metals, method of its production and method of water purification / 2336946
Claimed is sorbent, made in form of granules of highly-porous aluminium oxide with pore volume not less than 0.55 cm3/g, specific surface not less than 200 m2/g, representing assembly of nanofibres, connected together into rigid spongy structure and containing nano-sized particles of iron oxides, formed as layer on the surface of said granules in amount 2-10% from granules weight. Sorbent is obtained by impregnation of porous base with solution of iron compounds with further processing with alkali.
 Semiconductor photoelectric generator (versions) / 2336596
Invention concerns electronic technics, particularly devices converting electromagnetic emission energy into electric energy, and technologies of their manufacturing, particularly semiconductor photoelectric generators. Semiconductor photoelectric generator takes form of a matrix of commuted microphotoconverters with one or two linear dimensions comparable to diffusion length of secondary current carriers in base area; p-n transition planes are perpendicular to working surface of generator; microphotoconverter surface free of n-p transitions carries a 10-30 nm thick insulating film with 10-40 nm metal clusters positioned on it at 60-120 nm distance from each other; and dielectric layer of passivating antireflection coating is laid over nanoclusters. Two more embodiments of photoelectric generator are claimed.
 Method of obtaining nanotubular structures of oxides of vanadium or chrome subgroup (versions) / 2336230
Method of obtaining nanotubular structures includes mixing of oxygen-containing organic compound - oxalic acid hydrate with vanadium oxide gel or oxygen-containing compound of respective metal. As oxygen-containing compound of respective metal, peroxide molybdenum or tungsten oxides are used.
Heterostructure for photocathode / 2335031
Invention may be used in structures of photocathode in optoelectronic systems, secondary emission photocells, detector modules of ionising radiations, systems of images recognition, etc. According to invention, in heterostructure for photocathode that contains diamond layer of p-type conductivity with nanodimensional topological irregularities on its surface, as nanodimensional topological irregularities auto-emissive diamond points or diamond crystalline nanoparticles are used that are regularly positioned, surface of layer, except for the said irregularities, being covered with conducting amorphous carbon or nanocarbide film. Heterostructure may be installed on wafer, in which cavity is provided.
 Multipurpose biocompatible nanostructue membranulas for medicine / 2333009
The invention refers to biocompatible wearproof nanostructure thin-film materials on the basis of titan carbonitride, used as membranulas for manufacturing imlants, working under load. Total concentration of the basic and additional elements in a covering has the following ratio:
Nanocomposite material / 2332352
Invention concerns nanotechnologies and is designed for production of nanocomposite materials with efficiently adjustable optic properties, which can be applied in non-linear optics, IT, optic memory device development etc. Nanocomposite material contains nanoparticles, intermediary link molecules (particles changing their spatial configuration under the influence of external light source), and linked molecules (particles exhibiting some optic properties in vicinity of nanoparticles), all three components linked in sequence in a spatial cluster structure. Intermediary link molecules, changing their spatial configuration under the influence of external light source, can include additives - functional substitutes increasing their linking properties.
 Anti-leucosis and anti-microbial composition / 2339376
Invention relates to veterinary and medicine, particularly substances with cytostatic and bactericidal properties; it can be applied in pharmaceutical industry. The water-soluble composition includes, in wt %: 0.007 to 0.7 metronidazole, 0.0085 to 0.85 silver hexamethylenetetramine nitrate, 0.0284 to 2.84 sodium thiosulphate, water or physiological solution to 100.
![Dimers of pyrrol[2,1-c][1,4]benzodiazepine as antitumoral agents and method of their obtaining](http://img.russianpatents.com/img_data/162/1628552-s.gif) Dimers of pyrrol[2,1-c][1,4]benzodiazepine as antitumoral agents and method of their obtaining / 2338747
New derivatives of pyrrol[2,1-c][1,4]benzodiazepine of the general formula
 New physiologically active substances / 2338741
Invention pertains to new compounds with general formula (I)
 Polyactive terpenoid substance abisil-2, pharmaceutical composition on its basis and ways of its application / 2338547
Agent possessing wound-healthing, antiinflammatory, antibacterial, immunomodulating, anaesthetising and antitumoral activity on a basis of terpenoids, contains a capsule extract of plants of Pinaceae bloodline exposed to short-term stressful influence, enriched with monoterpenes, obtained from a capsule extract. The pharmaceutical composition possessing wound-healthing, antiinflammatory, antibacterial, immunomodulating, anaesthetising and antitumoral activity, contains the above described agent in effective quantity and the target additive. Application of the above described agent for preparation of a medicinal preparation for treatment of pyoinflammatory diseases.
Method of neoadjuvant chemotherapy of mammary gland cancer / 2338545
From the first day of treatment centrifugate the autoblood obtained by vascular access in volume of 2400-2600 ml, 1600 ml of supernatant plasmas select in sterile vials, expose to filtrational detoxicating with use of filter F60S with rate of perfusion of 250-300 ml/minute. Then the obtained albuminous concentrate of autoplasma in volume 700-800 ml place in sterile vials in the equal portions corresponding to number of planned introductions of cytostatics under the scheme. Vials contain in a refrigeration cabinet at t-20°C. At carrying out of polychemotherapy by cytostatics under the scheme, an albuminous concentrate defreeze at t +4°C, each antitumoral preparation plant in 10 ml of a normal saline solution, enter into a vial with an albuminous concentrate, incubate at t +37.0°C within not less than 30 minutes and reinfuse them intravenously driply, spend 1-2 courses of neoadjunt treatment.
Combined therapy for treatment of acute leukemia and myelodisplastic syndrome / 2338535
Invention can be used for treatment of an acute myelogenetic leukemia or myelodysplastic syndrome. For this purpose use a combination of preparations hemetuzumab ozohamicin, daunorubicin and cytarabinum in certain doses and regimens.
 Staufosporine derivatives as inhibitors of receptor tyrosine kinase flt3 activity / 2337692
Invention concerns application of N-[(9S,10R,11R,13R)-2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,9N-diindolo [1,2,3-gh:3', 2', 1'-lm] pyrrolo[3,4-j][1,7]benzodiasonine-11-yl]-N-methylbenzamide of formula
 Antitumoral agent on basis of immunopolisome biological structure, way of its obtaining and vectorial delivery in central nervous system at tumoral process / 2336901
Invention concerns biopharmacology and medicine area. The antitumor agent representing a immunoliposome biological structure, including a liposome containing the therapeutic agent, sewed with a vector of peptide nature, thus for treatment of CNS tumors is declared, the liposome contains the therapeutic agent in a water phase, as a vector contains monoclonal antibodies to CD34+, and a linking represents 2-iminotiolan (IT) in 0.1% concentration. As a therapeutic agent, immunoliposome contains the substance chosen from the group: Daunomycin, Carminomycinum, Melphtalan, Methotrexatum, Cytarabinum, Doxorubicinum, Ricine. The method of obtaining of an antitumoral agent and way of inhibition of a tumor of the brain, consisting in agent administering due to item 1 in a pharmaceutically suitable carrier in effective quantity is declared also. Thus preliminary administer parenterally a preparation of hematological stem cells CD34+.
Method of obtaining shelf fungus ethanolic extract / 2336888
Invention concerns the pharmaceutical, food and cosmetic industry. Perform extraction of the raw material crushed with water with obtaining of a water extract and pulp. The pulp, obtained after extraction of raw materials by the water, is extracted in two steps with ethyl alcohol. At the first step of extraction the constrictor is extracted within 4-6 hours using the following proportion: ethyl alcohol 1:(5-7) with concentration of alcohol of 30% either 50%, or 70%, at temperature of 60-75°C, obtaining an ethanolic extract of the first step of extraction and pulp; then, this pulp is repeatedly extracted within 4-6 hours with ethyl alcohol using the following proportion: ethyl alcohol 1:(3-5) with concentration of alcohol of 30% either 50%, or 70%, at temperature of 60-75°C, obtaining an ethanolic extract of the second step of extraction and pulp. After that the ethanolic extract of the first step of extraction is aggregated with the ethanolic extract of the second step of extraction.
 Pyrimidine derivatives, characterised by antiproliferative activity, and pharmaceutical composition / 2336275
Invention relates to new pyrimidine derivatives of formula I and their pharmaceutically acceptable salts, which are selective inhibitors of kinases KDR, FGFR and PDGFR and can be used for treatment of oncological diseases. Compound of formula I corresponds to structural formula
 Method of treatment of lacrimation insufficiency at ocular surface disease / 2338492
Originally do an eversion of an upper eyelid with a passive electrode imposed on a skin of an eyelid of an electrostimulator on a napkin moistened of 0.9% with a solution of chloride sodium. Make relocation of an electro stimulator by an active electrode on mucous eyelids and a transitive fold with preliminary anaesthesia by superficial anaesthetic. Thus make an aspiration of tear from an internal surface of the eyelid and transitive folds through an aperture on the working extremity of an active electrode which, by means of the longitudinal channel, is bridged to an aspiration tube and impact of a laser stimulating beam of 670 nanometers wavelength on mucous.
|
FIELD: medicine. SUBSTANCE: invention concerns medicine, namely, to oncology and can be used at treatment of malignant tumours. The essence of the declared method is the following: intravenously inject nanoparticles of phthalocyanines in a dose not below 5 mg/kg of weight and not above as much as possible tolerable dose with the subsequent irradiation of a tumour laser impulses with a wavelength in the field of intensive absorption nanoparticles at energy density in impulse not lower than 0.1 J/cm2 and total density of energy not lower than 10 J/cm2. EFFECT: increase of treatment efficiency of malignant tumours in comparison with earlier applied nanoparticles of carbon due to higher absorption coefficient of nanoparticles of phthalocyanines. 4 tbl, 4 ex
The present invention relates to medicine, namely to Oncology, and can be used in the treatment of malignant tumors. Known method of inducing cell death in vitro by introducing into them the nanoparticles (NPS) of gold, followed by irradiation of laser pulses (..Pitsillides, .K.Joe, X.Wei, R.R.Anderson, and C.P.Lin, Selective Cell Targeting with Light-Absorbing Microparticles and Nanoparticles, Biophysical Journal, 84, 4023-4032, 2003; V.P.Zharov, .N.Galitovskaya, C.Johnson, and T.Kelly. Synergistic Enhancement of Selective Nanophotothermolysis with Gold Nanoclusters: Potential for Cancer Therapy, Lasers in Surgery and Medicine 37, 219-226, 2005; V.P.Zharov, Keese, .N.Galitovskaya, and .S.Smeltzery. Photothermal Nanotherapeutics and Nanodiagnostics for Selective Killing of Bacteria Targeted with Gold Nanoparticles, Biophysical Journal, 90, 619-627, 2006). However, experiments on the effectiveness of LF gold in vitro have not been confirmed in vivo, which is closer to clinical application. The idea of the method in vivo is as follows. Animal are administered intravenously bass, which has an intense absorption in the red or near infrared region of the spectrum (wavelength of 0.6 to 1.2 μm, in the so-called "therapeutic window of transparency of biological tissue"). Then the tumor is irradiated by powerful laser pulses with a wavelength in the region of high absorption of LF. Under the action of each laser pulse occur "microexplosions" WOOFER, resulting in damage to surrounding tissue structures and the subsequent death of tumor cells. E is the efficiency effect is dose entered LF, the energy density of the laser pulse and the total energy density. Under other equal conditions is of great importance absorption coefficient introduced LF at the wavelength of irradiation, because it depends absorbed by each particle, the energy of the laser pulse (energy microexplosion) and, therefore, the value it produces destruction. Closest to the proposed solution is a method of inhibiting the growth of tumors in the experiment on animals (mice) by intravenous low carbon at a dose of 30 mg/kg with subsequent irradiation of the tumor by laser pulses in the spectral range of absorption bass with density pulse energy of 3 j/cm2and the total energy density of 180 j/cm2(B.Ya.Kogan, R.I.Yakubovskaya, A.A.Pankratov, T.N.Andreeva, L.D.Kvacheva, A.A.Titov, V.A.Puchnova, R.A.Feysulova, G.N.Vorozhtsov, Laser heating of sulphuretted carbon Danoparticles inhibits tumor growth. Technical Proc., NSTI Nanotech 2006, Boston, 2006, Vol.2, Chapter 1, p.71-74). The maximum inhibition of tumor growth (TRO) for carcinoma C-26 and sarcoma S-37 was reached 70-75%. The disadvantage of this method is its low efficiency, because at high enough energy density per pulse (3 j/cm2) and the total energy density (180 j/cm2) TRO is only 70-75%. The present invention is to increase the efficiency of this method, i.e. achieving the same or higher value is s TRO at lower energy densities of radiation. The problem is solved by intravenous LF phthalocyanines with subsequent irradiation of the tumor by laser pulses in LF absorption. The dose of nanoparticles is selected not less than 5 mg/kg weight (with further dose reduction significantly decreases the efficiency of the method) and not more than the maximum tolerated dose (MTD). The energy density of the pulse is not lower than 0.1 j/cm2(with a further reduction significantly decreases the efficiency of the method). The upper limit of the energy density of the pulse is associated with the capacity used laser. The total energy density is bounded from above valid session duration of exposure, and the lower value of 10 j/cm2(with a further reduction significantly decreases the efficiency of the method). Studies were performed on mice with transplantable solid tumors of different histogenesis. As thermoinsulation used the bass on the basis of various phthalocyanines. NP was injected intravenously in doses of MTD (maximum tolerated dose) and below. Then the tumor was irradiated with a pulse laser with a q-switched ruby. The energy density per pulse was not lower than 0.1 j/cm2the total energy density is not lower than 10 j/cm2. Evaluation of the antitumor effect was carried out on the inhibition of tumor growth (SRW, %), which was calculated by the formula: TRO (%)=[(the O controlRHOexperience)/RHOcontrol]×100, where RHOcontrol- the size of the tumor in the control group; RHOexperience- the size of the tumor in the experimental group. The invention is illustrated by the following examples. Example 1. LF aluminum phthalocyanine (AlPc) as thermogenerator. Studies were performed on mice with carcinoma C-26. Data characterizing the antitumor effectiveness of the method with NP AlPc presented in table 1. As can be seen from table 1, the irradiation of the tumor site by pulse laser radiation, after the introduction of thermogenerator in doses of 30 mg/kg (close to the MTD) to 7.5 mg/kg resulted in inhibition of tumor growth by up to 90% at a much lower energy density of radiation than in the prototype. Introduction WOOFER aluminum phthalocyanine in the studied doses without irradiation, and irradiation without entering the nanoparticles had no significant effect on tumor growth (TRO did not exceed 15%).
Example 2. LF of copper phthalocyanine (CuPc) as thermogenerator. Studies were performed in mice with sarcoma S-37. Data characterizing the antitumor effectiveness of the method with NP CuPc presented in table 2.
As can be seen from table 2, the irradiation of the tumor site at significantly smaller compared to the prototype energy densities after the introduction of the LF CuPc at a dose of 30 mg/kg exerted a pronounced therapeutic effect in 80% of animals observed complete regression of the tumor site. In some animals (20%)who have failed to achieve complete regression of tumors was observed TRO to a 99-89% (8 and 11 days after treatment). Introduction nanoparticles of copper phthalocyanine in the same dose without irradiation, and irradiation without entering the nanoparticles had no significant effect on tumor growth (TRO did not exceed 18%). Example 3. LF acids of octacarbonyldicobalt cobalt (Source) as thermosense is ilitator. Studies were performed in mice with sarcoma S-37. Data characterizing the antitumor efficacy with bass Source, are presented in table 3. As can be seen from the data presented in table 3, the irradiation of the tumor site at significantly smaller compared to the prototype energy densities after the introduction of the LF Source at a dose of only 5 mg/kg (close to the MTD) had comparable with the prototype antitumor activity, leading to inhibition of tumor growth by 65%. Introduction LF phthalocyanine cobalt in the same dose without irradiation, and irradiation without entering the LF had no significant effect on tumor growth (TRO did not exceed 15%).
Example 4. LF of zinc phthalocyanine (ZnPc) as thermogenerator. Studies were performed in mice with sarcoma S-37. Data characterizing the antitumor effectiveness of the method with NP ZnPc presented in table 4. As can be seen from the data presented in table 4, the irradiation of the tumor site at significantly smaller compared to the prototype energy densities after the introduction of nanoparticles ZnPc at a dose of 30 mg/kg resulted in inhibition of tumor growth up to 100%. Introduction LF phthalocyanine zinc in the same dose without irradiation, and irradiation without entering the nanoparticles had no significant effect on tumor growth (TRO did not exceed 16%).
These examples show that pulsed laser irradiation of tumors after intravenous LF phthalocyanines leads to more effective inhibition of tumor growth or even a complete cure at lower doses and lower energy densities of radiation in comparison with the use of low carbon. Thus, a method of inhibiting growth of tumors by intravenous nanoparticles phthalocyanines with subsequent irradiation of the tumor by laser pulses with a wavelength in the region of high absorption of the nanoparticles, having advantages over known similar method using nanoparticles of carbon. When smaller doses are entered WOOFER and smaller energy densities of radiation is best therapeutic effect until full recovery. The method of suppressing the growth of tumors by intravenous nanoparticles with subsequent irradiation of the tumor by laser pulses with a wavelength in the region of high absorption of the nanoparticles, characterized in that for intravenous use nanoparticles of phtalocyanine the dose of not less than 5 mg/kg and not exceeding the maximum tolerated dose of energy density per pulse is not lower than 0.1 j/cm 2and the total energy density not lower than 10 j/cm2.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||